Allergan’s Acular
Executive Summary
Ophthalmic form of the NSAID (ketorolac) approved for relief of ocular itching caused by seasonal allergic conjunctivitis. Acular will be manufactured and marketed by Allergan, which has world marketing rights except in Japan; Syntex will provide the active ingredient. Acular will be available in the U.S. "by early spring" in 10 ml dropper bottles with 5 ml of solution. Syntex sales of oral and intramuscular ketorolac (Toradol) for pain management totaled $149 mil. in the U.S. and $197.8 mil. worldwide in FY 1992 (ended July 31), the company said in its annual report. Additional formulations of ketorolac under development include a topical gel, a transdermal patch and a sustained-release twice-daily tablet.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth